Compare XPOF & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | AVXL |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 237.2M |
| IPO Year | 2021 | 2013 |
| Metric | XPOF | AVXL |
|---|---|---|
| Price | $4.59 | $1.32 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.60 | N/A |
| AVG Volume (30 Days) | 774.6K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.32 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.57 | $1.44 |
| 52 Week High | $9.25 | $9.50 |
| Indicator | XPOF | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 21.50 |
| Support Level | $4.50 | N/A |
| Resistance Level | $6.15 | $2.80 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 50.59 | 2.71 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.